ArticleMedicine2026
miR-130a-3p regulates the occurrence and progression of lung squamous cell carcinoma by activating ZDHHC5 and immune cell-related pathways.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prior investigations have indicated that the process of palmitoylation is crucial in the onset and progression of a variety of cancers. Nonetheless, its function in lung squamous cell carcinoma (LUSC) and the corresponding upstream and downstream regulatory networks remains inadequately explored. In this research, we aimed to elucidate the causal links and underlying mechanisms among microRNAs (miRNAs), palmitoylation-related genes, immune cell interactions, and LUSC using Mendelian randomization (MR) approaches. The study integrated 2-sample MR analysis, SMR analysis, differential gene expression examination, meta-analysis, single-cell investigation, and mediation assessment. Two-sample MR was employed to evaluate the causal impact of palmitoylation-associated genes on LUSC development, while SMR techniques and single-cell analyses were utilized to validate the association between gene expression patterns and LUSC. A notable positive association was observed between elevated expression levels of the ZDHHC5 gene and increased LUSC risk. Specifically, an increment of 1 standard deviation in ZDHHC5 expression corresponded to a 22.90% rise in LUSC risk. These findings were corroborated by differential gene expression analysis, meta-analysis, and validation at the single-cell level. Additional miRNA analysis revealed that miR-130a-3p indirectly influences LUSC development by modulating ZDHHC5 gene expression, with a mediation effect ratio of 95.67% (P = .038). Further mediation analysis explored the intermediary role of immune cells in the relationship between ZDHHC5 and LUSC, identifying CD28 on secreting regulatory T cells (Treg) with a mediation effect ratio of 16.59% (P = .033). The data indicate that miR-130a-3p exerts regulatory control over the ZDHHC5 gene, consequently modulating the function of CD28 on secreting Tregs, thereby promoting LUSC occurrence. These insights provide a novel theoretical foundation for the development of immunotherapeutic and targeted treatment strategies for LUSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.